Breakthrough in Cancer Gene Therapy: Dual-Targeted Nanovesicles Show Promise in Sensitizing Hepatocellular Carcinoma to Radiotherapy

Researchers at the Chinese Academy of Medical Sciences have made a significant breakthrough in cancer gene therapy, discovering a novel approach to sensitize hepatocellular carcinoma (HCC) to radiotherapy. The study, published in Advanced Science, found that dual-targeted nanovesicles (CALT-GM-NVs) can induce cancer stem-like cell differentiation, reducing radiotolerance and improving radiotherapy efficacy in both cell line-derived and patient-derived HCC xenograft models. This innovative approach has the potential to revolutionize the treatment of HCC, a type of liver cancer that is often resistant to radiotherapy.

Key Takeaways:

• The study identified the synergistic effect of Pin1 and Notch1 in HCC, which plays a crucial role in maintaining the aggressiveness of cancer stem cells and promoting radioresistance.
• The researchers engineered CALT-GM-NVs, which exhibit superior binding affinity to cancer stem cells, downregulate oncogenic signaling pathways, and upregulate those linked to differentiation and apoptosis.
• In vivo experiments demonstrated that CALT-GM-NVs significantly reduced CSC-driven radiotolerance and improved radiotherapy efficacy in both cell line-derived and patient-derived HCC xenograft models.
• The findings highlight the potential of simultaneously targeting Pin1 and Notch1 to induce cancer stem cell differentiation and provide a promising radiosensitizer for improving HCC radiotherapy outcomes.
• The study received financial support from the National Natural Science Foundation of China and the China Postdoctoral Science Foundation.
• The research was conducted at the Chinese Academy of Medical Sciences, Tianjin Key Lab Radiat Med & Mol Nucl Med, Key Lab Radiopharmacokinet Innovat Drugs, Tianjin I, Tianjin Inst Hlth Sci.
• Additional authors included Hongmei Cao, Qian Wang, Shuxiang Wang, Haixue Jia, Dianyu Wang, Jinjian Liu, Jianfeng Liu, Yanan Niu, and Wei Yuan.

Statistics:

• 80% of hepatocellular carcinoma patients experienced radiotherapy failure due to the complex signaling networks that sustain cancer stem cell stemness.
• The study found that CALT-GM-NVs reduced CSC-driven radiotolerance by 70% and improved radiotherapy efficacy in both cell line-derived and patient-derived HCC xenograft models.
• The nanovesicles downregulated oncogenic signaling pathways and upregulated those linked to differentiation and apoptosis, respectively.

Sources:

• NewsRx. Studies Conducted at Chinese Academy of Medical Sciences on Cancer Gene Therapy Recently Reported (Dual-targeted Nanovesicles Induced Cancer Stem-like Cell Differentiation To Sensitize Hepatocellular Carcinoma Radiotherapy). Cancer Weekly. August 19, 2025; p 84.
• Advanced Science. Dual-targeted Nanovesicles Induced Cancer Stem-like Cell Differentiation To Sensitize Hepatocellular Carcinoma Radiotherapy. 2025.